A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months
of ramucirumab administered in combination with paclitaxel and carboplatin as first-line
therapy for Stage IIIB or IV non-small cell lung cancer